Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARα/γ activation in 3T3-L1 cells

FEBS Letters

Volumn 582, Issue 23-24, 2008, Pages 3465-3472

  Kim, Su Nam ^a   Choi, Hye Young ^b   Lee, Woojung ^a   Park, Gab Man ^b   Shin, Woon Seob ^b   Kim, Yong Kee ^b  

^a Korea Institute of Science and Technology   (South Korea)

^b Catholic Kwandong University   (South Korea)

Author keywords

PPAR agonist; Sargahydroquinoic acid; Sargaquinoic acid; Sargassum yezoense

Indexed keywords

ADAPTOR PROTEIN; ADIPONECTIN; ALKENE DERIVATIVE; CCAAT ENHANCER BINDING PROTEIN ALPHA; GLUCOSE TRANSPORTER 4; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; SARGAHYDROQUINOIC ACID; SARGAQUINOIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; INSULIN RESISTANCE; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SARGASSUM; SCREENING TEST;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ALKENES; ANIMALS; BENZOQUINONES; MICE; PPAR ALPHA; PPAR GAMMA; SARGASSUM; TRANSCRIPTION, GENETIC;

SARGASSUM YEZOENSE;

EID: 53049093699     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.09.011     Document Type: Article

References (21)

1. Gervois P., Fruchart J.C., and Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 145-156
2. Cignarella A., Bellosta S., Corsini A., and Bolego C. Hypolipidemic therapy for the metabolic syndrome. Pharmacol. Res. 53 (2006) 492-500
3. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., Boland R., and Evans R.M. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. USA 99 (2002) 303-308
4. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1 (2004) S43-S50
5. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
6. Calkin A.C., Jandeleit-Dahm K.A., Sebekova E., Allen T.J., Mizrahi J., Cooper M.E., and Tikellis C. PPARs and diabetes-associated atherosclerosis. Curr. Pharm. Des. 13 (2007) 2736-2741
7. Henke B.R. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J. Med. Chem. 47 (2004) 4118-4127
8. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
9. Pourcet B., Fruchart J.C., Staels B., and Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert. Opin. Emerg. Drugs 11 (2006) 379-401
10. Balakumar P., Rose M., Ganti S.S., Krishan P., and Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol. Res. 56 (2007) 91-98
11. Ohmer J., Miller J.W., and Sasich L.D. Accessing FDA approval packages and briefing documents. Ann. Pharmacother. 41 (2007) 2071-2072
12. Bailey C.J. Learning from tesaglitazar. Diab. Vasc. Dis. Res. 4 (2007) 161-162
13. Balunas M.J., and Kinghorn A.D. Drug discovery from medicinal plants. Life Sci. 78 (2005) 431-441
14. Kim Y.K., et al. Reversine stimulates adipocyte differentiation and downregulates Akt and p70(s6k) signaling pathways in 3T3-L1 cells. Biochem. Biophys. Res. Commun. 358 (2007) 553-558
15. Soukas A., Socci N.D., Saatkamp B.D., Novelli S., and Friedman J.M. Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J. Biol. Chem. 276 (2001) 34167-34174
16. Kamei Y., and Tsang C.K. Sargaquinoic acid promotes neurite outgrowth via protein kinase A and MAP kinases-mediated signaling pathways in PC12D cells. Int. J. Dev. Neurosci. 21 (2003) 255-262
17. Perez-Castorena A.L., Arciniegas A., Apan M.T., Villasenor J.L., and de Vivar A.R. Evaluation of the anti-inflammatory and antioxidant activities of the plastoquinone derivatives isolated from Roldana barba-johannis. Planta Med. 68 (2002) 645-647
18. Mayer A.M., and Gustafson K.R. Marine pharmacology in 2003-2004: anti-tumour and cytotoxic compounds. Eur. J. Cancer 42 (2006) 2241-2270
19. Mayer A.M., and Hamann M.T. Marine pharmacology in 2001-2002: marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 140 (2005) 265-286
20. Hur S., Lee H., Kim Y., Lee B.H., Shin J., and Kim T.Y. Sargaquinoic acid and sargachromenol, extracts of Sargassum sagamianum, induce apoptosis in HaCaT cells and mice skin: its potentiation of UVB-induced apoptosis. Eur. J. Pharmacol. 582 (2008) 1-11
21. Park B.G., et al. Selective vasodilatation effect of sargahydroquinoic acid, an active constituent of Sargassum micracanthum, on the basilar arteries of rabbits. Bioorg. Med. Chem. Lett. 18 (2008) 2624-2627